Competition Law Insight
Hot flush
UK watchdog concerns in HRT merger could be remedied through divestment commitments
by Macrui Dostourian
The UK's Competition and Markets Authority (CMA) has concerns
that London-based global pharmaceuticals company Theramex's proposed purchase of the European rights to
US-based Viatris' Femoston and Duphaston product lines may reduce both competition and choice in the market
for hormone replacement therapy (HRT) treatments. HRT, which can be taken either as a pill or applied on the
skin through a patch, gel or spray, is used to treat menopause symptoms such as hot flushes, joint pain and
mood swings.